Rajangam Jayaraman, Krishnan Navaneetha, Palei Narahari N, Bhatt Shvetank, Das Manas Kumar, Das Saumya, Mathusoothanan Krishnapillai
Sree Vidyanikethan College of Pharmacy, Department of Pharmacology, Andhra Pradesh, India
Sree Vidyanikethan College of Pharmacy, Department of Pharmaceutics, Andhra Pradesh, India
Turk J Pharm Sci. 2022 Feb 28;19(1):28-34. doi: 10.4274/tjps.galenos.2021.70745.
The study aimed to explore the protective potential of rosuvastatin (ROSS), an oral antihyperlipidemic drug against doxorubicin (DOXO) induced cardio toxicity in rats.
Cardiac toxicity was induced by DOXO injection (10 mg/kg, ), once on the 20 day of the experiment. Except for the control rats, all were received DOXO and the study was continued for up to 21 days. The influence of ROSS on acute treatment was analyzed by quantification of cardiac marker enzymes such as creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH) and liver marker enzymes like aspartate aminotransferase (AST), alanine aminotransferase (ALT) along with the measurement of antioxidants like superoxide dismutase and catalase. To observe histological changes of myocardial tissue hematoxylin and eosin staining were used.
Acute administration of DOXO resulted in a marked rise of cardiac marker enzymes that confirms the myocardial damage compared to control animals whereas administration of ROSS (10 mg/kg, ) resulted in the significant reduction of CK-MB, LDH levels (<0.05) and AST, ALT levels to a remarkable extent. Moreover, ROSS administration significantly increased the activities of various antioxidant levels.
From the results, the acute administration of ROSS showed significant cardioprotective property, which was evidenced by a significant reduction of cardiac and liver marker enzymes along with significant improvement of antioxidant activities. Furthermore the results were supported with histopathological observations. Hence, it can be concluded that cardioprotective potential of ROSS may be through attenuation of oxidative stress by modulating oxidative damage in rats.
本研究旨在探讨口服抗高脂血症药物瑞舒伐他汀（ROSS）对阿霉素（DOXO）诱导的大鼠心脏毒性的保护潜力。
在实验的第20天，通过注射DOXO（10mg/kg）诱导心脏毒性，仅注射一次。除对照大鼠外，所有大鼠均接受DOXO处理，并持续研究21天。通过定量分析心脏标志物酶如肌酸激酶同工酶（CK-MB）、乳酸脱氢酶（LDH）以及肝脏标志物酶如天冬氨酸转氨酶（AST）、丙氨酸转氨酶（ALT），并测量超氧化物歧化酶和过氧化氢酶等抗氧化剂，分析ROSS对急性治疗的影响。使用苏木精和伊红染色观察心肌组织的组织学变化。
与对照动物相比，急性给予DOXO导致心脏标志物酶显著升高，证实了心肌损伤；而给予ROSS（10mg/kg）可显著降低CK-MB、LDH水平（<0.05），并在很大程度上降低AST、ALT水平。此外，给予ROSS可显著提高各种抗氧化剂水平的活性。
结果表明，急性给予ROSS具有显著的心脏保护作用，表现为心脏和肝脏标志物酶显著降低以及抗氧化活性显著提高。此外，组织病理学观察也支持了这些结果。因此，可以得出结论，ROSS的心脏保护潜力可能是通过调节大鼠的氧化损伤来减轻氧化应激。
